Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Breast Cancer”

628 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 628 results

Testing effectiveness (Phase 2)Ended earlyNCT00417885
What this trial is testing

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Who this might be right for
Breast Neoplasms
Pfizer 6
Not applicableActive Not RecruitingNCT05730647
What this trial is testing

Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients

Who this might be right for
Early Breast Cancer
Consorzio Oncotech 600
Very early researchStudy completedNCT02538484
What this trial is testing

Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

Who this might be right for
Breast Cancer
The University of Texas Health Science Center at San Antonio 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT01984138
What this trial is testing

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

Who this might be right for
Estrogen Receptor Positive Breast CancerBreast Cancer
Polly A. Niravath, MD 33
Testing effectiveness (Phase 2)Study completedNCT03219476
What this trial is testing

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Who this might be right for
Breast CancerInvasive Breast Cancer
Medical College of Wisconsin 37
Large-scale testing (Phase 3)Ended earlyNCT01303679
What this trial is testing

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Who this might be right for
First Line Metastatic Breast Cancer
ARCAGY/ GINECO GROUP 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT04576455
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 303
Post-approval studies (Phase 4)Not Yet RecruitingNCT04137640
What this trial is testing

Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
Shengjing Hospital 152
Not applicableStudy completedNCT01385280
What this trial is testing

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerProgesterone Receptor Positive TumorRecurrent Breast Cancer+2 more
University of Arizona 13
Not applicableStudy completedNCT00830973
What this trial is testing

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

Who this might be right for
Breast NeoplasmsTamoxifen
Medco Health Solutions, Inc. 184
Early research (Phase 1)Looking for participantsNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 48
Testing effectiveness (Phase 2)Ended earlyNCT04504916
What this trial is testing

Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Who this might be right for
Triple-negative Breast CancerNon-squamous Non-small-cell Lung CancerNSCLC+12 more
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 102
Early research (Phase 1)WithdrawnNCT01320787
What this trial is testing

18-F-Fluoroacetate as PET Imaging Agent

Who this might be right for
Brain CancerBreast CancerProstate Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT04824014
What this trial is testing

4FMFES-PET Imaging of ER+ Advanced Breast Cancers

Who this might be right for
ER+ Breast Cancer
Centre de recherche du Centre hospitalier universitaire de Sherbrooke 150
Testing effectiveness (Phase 2)Study completedNCT00003199
What this trial is testing

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast CancerInflammatory Breast Cancer+5 more
Fred Hutchinson Cancer Center 50
Testing effectiveness (Phase 2)Ended earlyNCT02202746
What this trial is testing

Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerMBC+5 more
Clovis Oncology, Inc. 178
Not applicableLooking for participantsNCT04101656
What this trial is testing

Accelerated Partial Irradiation of the Breast: New Altered Fractionation

Who this might be right for
Breast Cancer
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 174
Large-scale testing (Phase 3)Looking for participantsNCT05774951
What this trial is testing

Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Who this might be right for
Breast Cancer, Early Breast Cancer
AstraZeneca 4,300
Testing effectiveness (Phase 2)Study completedNCT03106077
What this trial is testing

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+18 more
M.D. Anderson Cancer Center 96
Testing effectiveness (Phase 2)Study completedNCT01439711
What this trial is testing

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 108
Load More Results